Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Patients with rheumatoid arthritis who undergo immune checkpoint inhibition for metastatic non-small cell lung cancer demonstrate similar overall survival as those without RA, according to data ...

Improvements in rural cancer care in Kentucky could be imperiled by President Trump's tax and domestic policy bill.

The global keloid treatment market is on a robust growth trajectory, with an estimated value of USD 4,135.1 million in 2025. Projections indicate a substantial expansion to USD 5,975.7 million by 2035 ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

Bristol-Myers Squibb recently wrapped up a pivotal study in Japan, focusing on the quality of life in patients with ...

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

"BikeTown Africa," a nonprofit organization, delivered more than 200 bikes to rural Africa to provide life-saving and ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to the treatment, leading to positive outcomes for patients, according to new ...

Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data. The stock ...

Ninety-three percent of hospitals responding to a recent survey conducted by 340B Health said they would struggle to maintain current levels of uncompensated care in the wake of drugmakers’ proposed ...